Principal Investigators

    Henrik Zetterberg


    Gothenborg University

    Contact information of lead PI



    Title of project or programme

    Pathways to Alzheimer’s disease

    Source of funding information

    The Swedish Brain Foundation

    Total sum awarded (Euro)

    € 108,814

    Start date of award


    Total duration of award in years



    Research Abstract

    Using patient materials in conjunction with cell, zebrafish and hippocampal slice models, we will address four major hypotheses of fundamental importance to the AD research field:
    (i) Many patients diagnosed with clinical AD do not have AD neuropathology.
    (ii) Amyloid build-up in AD is caused by imbalance in the production and clearance of specific Abeta
    (iii) Abeta needs brain incubation over years to become toxic.
    (iv) Gamma-Secretase dysfunction and/or microglial activation mediate Abeta toxicity.
    The uniqueness of the project lies in the combination of well-characterised clinical materials (including cerebrospinal fluid samples [CSF; the fluid that surrounds the brain and communicates freely with the brain interstitial fluid] and brain specimens), state-of-the-art clinical laboratory testing, groundbreaking approaches to biomarker discovery, and both novel and established animal and cell models. The proposed research is translational and involves clinical and pre-clinical units at the Sahlgrenska University Hospital and the Sahlgrenska Academy, as well as several national and
    international collaborators.

    Further information available at:

Types: Investments < €500k
Member States: Sweden
Diseases: N/A
Years: 2016
Database Categories: N/A
Database Tags: N/A

Export as PDF